[{"id":"be1f4791-7f5f-42b3-86ee-a6bfee99acee","acronym":"ASSURE","url":"https://clinicaltrials.gov/study/NCT04008706","created_at":"2021-01-18T19:41:49.844Z","updated_at":"2025-02-25T14:07:28.508Z","phase":"Phase 3","brief_title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04008706 - ASSURE","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • CD20 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • IGH mutation","tags":["TP53 • CD20 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-17"},{"id":"cf9e772d-2d61-448f-ba42-778f71f83dc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169737","created_at":"2021-01-18T20:20:34.948Z","updated_at":"2025-02-25T15:26:14.343Z","phase":"Phase 2","brief_title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT04169737","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 07/09/2026","primary_completion_date":" 07/09/2026","study_txt":" Completion: 07/09/2026","study_completion_date":" 07/09/2026","last_update_posted":"2025-02-10"},{"id":"ee309a82-4f0b-426f-a0b1-deeeabf2fd59","acronym":"","url":"https://clinicaltrials.gov/study/NCT04802161","created_at":"2021-03-17T15:57:34.517Z","updated_at":"2025-02-25T16:32:23.537Z","phase":"Phase 2","brief_title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","source_id_and_acronym":"NCT04802161","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2","pipe":" | ","alterations":" Chr del(11q)","tags":["RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide • thalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"a3defc3d-df49-43a3-8fb7-35111287e449","acronym":"NCI-2016-00797","url":"https://clinicaltrials.gov/study/NCT02756897","created_at":"2021-01-18T13:30:56.475Z","updated_at":"2025-02-25T17:23:07.242Z","phase":"Phase 2","brief_title":"Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia","source_id_and_acronym":"NCT02756897 - NCI-2016-00797","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 07/07/2016","start_date":" 07/07/2016","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-31"},{"id":"24c91644-22bc-4249-aaa6-106bdc7c0471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03524235","created_at":"2021-01-18T17:21:46.884Z","updated_at":"2024-07-02T16:34:59.315Z","phase":"Phase 1","brief_title":"Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","source_id_and_acronym":"NCT03524235","lead_sponsor":"Noah Merin","biomarkers":" MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression","tags":["MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 11/07/2021","primary_completion_date":" 11/07/2021","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-04"},{"id":"47419cad-33d1-4efc-a6a0-f1c6cbbcc254","acronym":"","url":"https://clinicaltrials.gov/study/NCT02518555","created_at":"2021-01-18T12:10:14.260Z","updated_at":"2024-07-02T16:35:02.891Z","phase":"Phase 2","brief_title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT02518555","lead_sponsor":"Jennifer Woyach","biomarkers":" TP53","pipe":" | ","alterations":" Chr del(11q) • Chr del(17)(p13.1)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q) • Chr del(17)(p13.1)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/12/2016","start_date":" 01/12/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"be1b1cbc-6baf-4848-9f92-082e2b4cd6b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01203722","created_at":"2021-01-18T04:49:23.205Z","updated_at":"2024-07-02T16:35:15.050Z","phase":"Phase 1/2","brief_title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","source_id_and_acronym":"NCT01203722","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-13"},{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"2bab9c7d-960f-48ce-83cf-ed84479f7a0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01750567","created_at":"2021-01-18T07:40:45.979Z","updated_at":"2024-07-02T16:35:38.532Z","phase":"Phase 2","brief_title":"A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL","source_id_and_acronym":"NCT01750567","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" CD20 positive • Chr del(11q)","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-08-31"},{"id":"aa180889-651b-45bf-a38a-fec50012bf96","acronym":"SWOG-C10404","url":"https://clinicaltrials.gov/study/NCT00602459","created_at":"2021-01-18T02:14:04.674Z","updated_at":"2024-07-02T16:35:47.517Z","phase":"Phase 2","brief_title":"Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00602459 - SWOG-C10404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr del(11q)","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 418","initiation":"Initiation: 01/15/2008","start_date":" 01/15/2008","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 04/15/2023","study_completion_date":" 04/15/2023","last_update_posted":"2023-05-22"},{"id":"0b5d05fa-af58-471b-8f6c-aaa3c0faf618","acronym":"GENUINE","url":"https://clinicaltrials.gov/study/NCT02301156","created_at":"2021-01-17T18:01:38.285Z","updated_at":"2024-07-02T16:36:10.097Z","phase":"Phase 3","brief_title":"Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT02301156 - GENUINE","lead_sponsor":"TG Therapeutics, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Briumvi (ublituximab-xiiy)"],"overall_status":"Completed","enrollment":" Enrollment 126","initiation":"Initiation: 01/27/2015","start_date":" 01/27/2015","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2022-05-20"},{"id":"43cc2176-b27f-4bca-b397-b12e19417b2d","acronym":"iLLUMINATE ","url":"https://clinicaltrials.gov/study/NCT02264574","created_at":"2021-01-17T17:35:09.358Z","updated_at":"2024-07-02T16:36:40.852Z","phase":"Phase 3","brief_title":"A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT02264574 - iLLUMINATE ","lead_sponsor":"Pharmacyclics LLC.","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 10/06/2014","start_date":" 10/06/2014","primary_txt":" Primary completion: 03/26/2018","primary_completion_date":" 03/26/2018","study_txt":" Completion: 09/03/2019","study_completion_date":" 09/03/2019","last_update_posted":"2020-09-21"},{"id":"115cdfb7-b7ec-4425-8237-e490f865d24d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02481297","created_at":"2021-01-18T11:56:53.230Z","updated_at":"2025-02-25T14:35:40.889Z","phase":"Phase 2","brief_title":"Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients","source_id_and_acronym":"NCT02481297","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lirilumab (BMS-986015)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 06/23/2015","start_date":" 06/23/2015","primary_txt":" Primary completion: 08/15/2019","primary_completion_date":" 08/15/2019","study_txt":" Completion: 08/15/2019","study_completion_date":" 08/15/2019","last_update_posted":"2020-05-28"},{"id":"fe92fdc8-a6cc-4f7e-b693-b575fed6d7de","acronym":"","url":"https://clinicaltrials.gov/study/NCT01118234","created_at":"2021-01-18T04:26:04.369Z","updated_at":"2024-07-02T16:36:51.546Z","phase":"Phase 3","brief_title":"Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)","source_id_and_acronym":"NCT01118234","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" CD38","pipe":" | ","alterations":" Chr del(11q) • CD38 expression • TS 12","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q) • CD38 expression • TS 12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 256","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2020-01-09"},{"id":"86465a30-842f-4ee8-a4ff-beb670073dbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01520519","created_at":"2021-01-18T06:23:45.968Z","updated_at":"2024-07-02T16:36:55.645Z","phase":"Phase 2","brief_title":"Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients","source_id_and_acronym":"NCT01520519","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 02/27/2012","start_date":" 02/27/2012","primary_txt":" Primary completion: 08/09/2018","primary_completion_date":" 08/09/2018","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2019-09-18"},{"id":"d8424f36-d614-46d5-bad3-44cf844d290f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00829647","created_at":"2021-01-18T03:09:26.471Z","updated_at":"2025-02-25T14:30:38.465Z","phase":"Phase 1/2","brief_title":"A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00829647","lead_sponsor":"Scripps Health","biomarkers":" CD38","pipe":" | ","alterations":" Chr del(11q)","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • lenalidomide • Campath (alemtuzumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2019-04-11"}]